Most sponsors recognize that 505(b)(2) can accelerate development, but fewer appreciate how early the strategy can go wrong. The wrong reference listed drug (RLD), an underestimated bridging package, or a poorly timed patent certification can erase the pathway’s advantages before the first pivotal study reads out.
When executed well, the 505(b)(2) pathway offers a legitimate accelerator for drug modifications: reformulations, new strengths, alternative routes of administration, new indications, and fixed-dose combinations. It allows sponsors to rely on FDA’s prior findings of safety and efficacy for an approved drug while generating only the data necessary to support what’s different. The result can be a shorter timeline, lower development cost, and reduced clinical risk, without compromising regulatory rigor.
Complete the form to download a copy of the article.
Get the full article
"*" indicates required fields
